Licensing
To augment its initial novel therapy for brain cancer, Bradmer Pharmaceuticals actively engages industry and academic collaborators regarding the expansion of its product portfolio.  The Company intends to acquire or in-license other clinical stage technologies for rapid development.  Bradmer’s strategy includes the assembly of a product portfolio featuring a diversity of molecular targets, disease indications, and drug approaches.  Such technologies will leverage the expertise of the Bradmer team in the field of novel, targeted therapies for cancer.

 

Distribution
Bradmer Pharmaceuticals controls the worldwide marketing rights to its currently licensed novel therapies for cancer.  The Company currently does not market any products.

 

Business Development Contact
Parties interested in discussing licensing or distribution partnerships with Bradmer Pharmaceutucals should contact us at info@bradmerpharma.com.